Company
Headquarters: Lure, France
Employees: 2,525
CEO: Mr. Matthieu Frechin
€998.7 Million
EUR as of Jan. 1, 2026
US$1.17 Billion
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of pain management, anti-infective, cardiology-nephrology, care and hygiene, antiparasiticides, behavior, internal medicine, and reproduction for cats, dogs, cattle, and pigs. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.
| Last Financial Reports Date | June 30, 2025 |
| Revenue TTM | €532.4 M |
| EBITDA | €113.0 M |
| Gross Profit TTM | €308.2 M |
| Profit Margin | 11.26% |
| Operating Margin | 13.49% |
| Quarterly Revenue Growth | -2.60% |
Vetoquinol SA has the following listings and related stock indices.
Stock: Euronext: VETO wb_incandescent
Stock: FSX: 8JM wb_incandescent